A 52-year-old man with a 10-year history of GERD presents with persistent epigastric pain and regurgitation despite taking ranitidine 300 mg twice daily for the past 6 months. Upper endoscopy reveals a 2 cm ulcer in the gastric antrum with no evidence of malignancy on biopsy. H. pylori serology is negative. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has a documented gastric ulcer despite adequate H₂-blocker therapy. The failure of H₂-receptor antagonist monotherapy to heal the ulcer indicates inadequate acid suppression for this lesion. ## Why PPI Is Superior Here **Key Point:** Proton pump inhibitors (PPIs) are the gold standard for gastric ulcer healing and achieve superior acid suppression compared to H₂ blockers. | Feature | H₂ Blocker (Ranitidine) | PPI (Omeprazole) | |---------|------------------------|------------------| | **Acid suppression** | ~70% reduction | >90% reduction | | **Gastric ulcer healing rate** | 70–80% at 8 weeks | >95% at 4 weeks | | **Mechanism** | Competitive antagonism | Irreversible proton pump inhibition | | **Onset** | 1–2 hours | 1–3 days (cumulative) | | **Duration** | 6–8 hours | 24–48 hours | **High-Yield:** PPIs are indicated for: - Gastric ulcers refractory to H₂ blockers - Severe erosive esophagitis - Zollinger–Ellison syndrome - Long-term GERD management ## Management Algorithm ```mermaid flowchart TD A[Gastric ulcer on endoscopy]:::outcome --> B{H. pylori status?}:::decision B -->|Positive| C[Triple/Quadruple therapy + PPI]:::action B -->|Negative| D{Adequate H2 blocker trial?}:::decision D -->|Yes, failed| E[Switch to PPI 20-40 mg daily]:::action D -->|No| F[Optimize H2 blocker dose]:::action E --> G[Reassess endoscopy at 4-8 weeks]:::action G --> H{Healed?}:::decision H -->|Yes| I[Continue PPI for 4-8 more weeks]:::action H -->|No| J[Investigate for NSAID use, malignancy, or ZES]:::urgent ``` **Clinical Pearl:** Gastric ulcers require longer healing times than duodenal ulcers (8 weeks vs. 4 weeks). The patient should be reassessed endoscopically after 4 weeks on PPI to confirm healing trajectory. ## Why Other Options Are Suboptimal - **Sucralfate addition:** Provides mucosal cytoprotection but does not address the underlying inadequate acid suppression; ineffective as monotherapy for ulcer healing. - **Increasing ranitidine:** The patient is already on a standard therapeutic dose (300 mg BD = 600 mg/day). Further escalation will not overcome the ceiling effect of H₂-blocker efficacy. - **24-hour pH monitoring:** Unnecessary at this stage; the clinical problem is not diagnostic uncertainty but treatment failure. pH monitoring is reserved for refractory symptoms or suspected hypersecretory states (Zollinger–Ellison).